Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 14/20 | 0.55 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.55 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.55 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6113338 | 0.89 | S1PR1 (0.48) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL6113260 | 0.86 | S1PR1 (0.54) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL6113117 | 0.84 | S1PR1 (0.55) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL6112950 | 0.84 | S1PR1 (0.54) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL6113340 | 0.83 | S1PR1 (0.53) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL86567 | 0.82 | S1PR1 (0.61) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL17733489 | 0.81 | S1PR1 (0.59) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL86676 | 0.81 | S1PR1 (0.59) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL86686 | 0.81 | S1PR1 (0.56) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL1982037 | 0.79 | S1PR1 (0.39) | S1PR1S1PR3S1PR4S1PR5S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703746-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-20140057876-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2014-02-27 | — | — | US | claimed |
| US-8653270-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-02-18 | — | — | US | claimed |
| US-20120129813-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. | 2012-05-24 | — | — | US | claimed |
| US-8703746-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140057876-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8653270-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2643331-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | Allergan, Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012071278-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| US-20120129813-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129813-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885S1PR4 4/4885 |
| US-20140057876-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885S1PR4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.